204 related articles for article (PubMed ID: 12176557)
1. Cyclosporine absorption profiling and therapeutic drug monitoring using C(2) blood levels in stable renal allograft recipients.
Einecke G; Mai I; Diekmann F; Fritsche L; Neumayer HH; Budde K
Transplant Proc; 2002 Aug; 34(5):1738-9. PubMed ID: 12176557
[No Abstract] [Full Text] [Related]
2. Optimizing Neoral therapeutic drug monitoring with cyclosporine trough (C(0)) and C(2) concentrations in stable renal allograft recipients.
Einecke G; Mai I; Diekmann F; Fritsche L; Boehler T; Neumayer HH; Budde K
Transplant Proc; 2001; 33(7-8):3102-3. PubMed ID: 11750333
[No Abstract] [Full Text] [Related]
3. Cyclosporine peak concentration in relation to the four-hour absorption phase in pediatric renal graft recipients.
Wigger M; Drückler E; Muscheites J; Stolpe HJ; Kundt G; Wacke R
Transplant Proc; 2001; 33(7-8):3126-7. PubMed ID: 11750344
[No Abstract] [Full Text] [Related]
4. Pharmacokinetics of abbreviated AUC of cyclosporine in renal allograft recipients in a Pakistani population.
Zafar MN; Abbas K; Naqvi A; Rizvi A
Transplant Proc; 1999 Dec; 31(8):3304. PubMed ID: 10616486
[No Abstract] [Full Text] [Related]
5. Experience with conversion from Sandimmun to Neoral cyclosporine and the correlation of C2 levels with renal function.
Konstadinidou I; Boletis JN
Transplant Proc; 2004 Mar; 36(2 Suppl):163S-166S. PubMed ID: 15041329
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A: peak or trough level monitoring in renal transplant recipients?
Wacke R; Drewelow B; Kundt G; Hehl EM; Bast R; Seiter H
Transplant Proc; 2001; 33(7-8):3122-3. PubMed ID: 11750342
[No Abstract] [Full Text] [Related]
7. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
[No Abstract] [Full Text] [Related]
8. C2 monitoring and absorption profiling of cyclosporine for optimization of immunosuppressive therapy in pediatric renal transplant recipients.
Weber LT; Shipkova M; Armstrong VW; Mehls O; Oellerich M; Tönshoff B;
Transplant Proc; 2003 Sep; 35(6):2128-30. PubMed ID: 14529863
[No Abstract] [Full Text] [Related]
9. Cyclosporine Neoral profiling in Japanese renal transplant recipients.
Aikawa A; Arai K; Tajima E; Kawamura T; Ogiwara H; Sakai K; Mizuiri S; Ohara T; Hasegawa A; Kosugi T; Kusano A; Matsuo K; Obayashi M; Kurokawa M
Transplant Proc; 2001; 33(7-8):3142-5. PubMed ID: 11750350
[No Abstract] [Full Text] [Related]
10. Predictive value of cyclosporine blood levels during the absorption phase to estimate the area under the curve in stable renal transplant patients.
Sabaté I; Calzada P; Gil-Vernet S; Fulladosa X; Baró S; González C; Castro MJ; Castelao AM; Grinyó JM
Transplant Proc; 2002 Feb; 34(1):140-1. PubMed ID: 11959224
[No Abstract] [Full Text] [Related]
11. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant.
Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY
Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892
[No Abstract] [Full Text] [Related]
12. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
Vathsala A; Lu YM
Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
[No Abstract] [Full Text] [Related]
13. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.
Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S
Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379
[No Abstract] [Full Text] [Related]
14. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
Wong HS; Morad Z
Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
[No Abstract] [Full Text] [Related]
15. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
[No Abstract] [Full Text] [Related]
16. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
Chueh SC; Liao CH; Lai MK
Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
Vathsala A; Lee WT; Lu YM; Woo KT
Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
[No Abstract] [Full Text] [Related]
18. Pharmacodynamic monitoring of lymphocyte proliferation and TGF-beta 1 expression at cyclosporine a (CyA) trough levels (C(0)) and 2 hours after intake (C(2)) of CyA in human renal allograft recipients.
Böhler T; Budde K; Schneider M; Eliazyfer S; Dell K; Einecke G; Diekmann F; Fritsche L; Mai I; Neumayer HH; Waiser J
Transplant Proc; 2001; 33(7-8):3148-50. PubMed ID: 11750352
[No Abstract] [Full Text] [Related]
19. Pharmacokinetic study of twice vs thrice daily dosing of Sandimmun Neoral in pediatric renal transplant patients.
Papachristou F; Gakis D; Sotiriou I; Liatsis I; Takoudas D; Antoniadis A
Transplant Proc; 1998 Aug; 30(5):1988-90. PubMed ID: 9723363
[No Abstract] [Full Text] [Related]
20. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
